HPV vaccination: How the world can eliminate cervical cancer

Original Article ↗ Hacker News Discussion ↗

Benefits and scope of HPV vaccination

  • HPV is linked not only to cervical cancer but also anal, penile, vulvar, vaginal, and head/neck cancers; commenters stress it’s a “universal win” for cancer prevention.
  • The 9‑valent vaccine (Gardasil 9) targets nine strains; even with prior exposure to one, others remain preventable.
  • Some participants mention evidence or clinical impressions that vaccination may help clear existing infections or reduce progression to precancer, but note this is not yet firmly established.

Men, gender framing, and herd immunity

  • Many criticize campaigns for framing HPV vaccination as “for girls,” leading men to underestimate their own cancer risk.
  • HPV-driven oropharyngeal cancer in men is highlighted as a major and rising problem.
  • Several argue for vaccinating all genders for both personal protection and herd immunity, and see current female-focused policies as unfair and counterproductive.

Age limits, access, and cost

  • In multiple countries, public coverage ends at a relatively young age (often mid‑20s or 30), leaving older adults to pay hundreds of euros/dollars out of pocket.
  • Some older men and women report being discouraged or dismissed by doctors when requesting vaccination outside guidelines, even when they have low past exposure or new partners.
  • Others describe getting it privately or via pharmacies/sexual‑health clinics; prices and schedules (1–3 doses) vary widely by country.

Real‑world cancer experiences

  • Several survivors of HPV‑related and non‑HPV oral cancers describe brutal treatment (surgery, radiation, feeding tubes, chronic pain, loss of taste/saliva, speech and hearing changes).
  • These stories are used to argue that reducing HPV‑related cancers is about avoiding lifelong morbidity, not just mortality.

Safety, trials, and controversy

  • Most posters consider HPV vaccines very safe; serious adverse events in trials were judged unrelated to vaccination.
  • Skeptical voices question the lack of placebo arms in newer trials, the attribution of serious events, and see “no‑placebo for ethical reasons” as flawed or pseudo‑scientific.
  • Some anti‑vaccine talking points appear (e.g., questioning long‑term safety, drawing parallels to COVID vaccine debates); others rebut them with trial data and risk comparisons.

Trust, politics, and misinformation

  • Participants link low HPV uptake to political polarization, distrust of institutions, and confusion from COVID‑era messaging.
  • Several worry that COVID‑related “authoritative disinformation” and anti‑vax resurgence will undermine HPV vaccination and cancer‑prevention efforts.